OCT 09, 2019 9:00 AM PDT

Start at the End: A Strategy for Developing and Delivering Advanced Diagnostic Tests to improve Prostate Cancer Patient Outcomes

Sponsored by: Agilent
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor of Proteomics, Founder, CEO and CSO Atturos Ltd. C/O UCD Conway Institute University College Dublin
    BIOGRAPHY

Abstract

Although about one in every seven men in the developed world will be diagnosed with prostate cancer in their lifetime, the mortality rate remains low with a 99% five-year survival rate for low to intermediate grade disease. Following diagnosis, surgery (radical prostatectomy), radiation therapy, hormonal therapy and chemotherapy either singly or in combinations are options for initial treatment. However, active surveillance - where disease progression is carefully monitored - may be a more appropriate option for less advanced and low grade disease.

At present a diagnosis of prostate cancer is initially and most commonly made on the basis of three investigations: the prostate specific antigen (PSA) test, digital rectal examination (DRE) and biopsy-based grading of the tumour by histopathology. It is accepted that these tests do not provide adequate information to support the decision of whether to pursue immediate treatment or active surveillance. Hence, there is a significant unmet need for specific and sensitive biomarkers to guide the decision between treatment and active surveillance, as well as for regular monitoring of disease progression in men on active surveillance.  

Despite a few decades of proteomics research and the apparent discovery of multiple protein biomarkers to support the diagnosis and treatment decisions, the number of protein biomarkers that have been developed to the stage of being used routinely is disappointingly low.  So, it's clear that whilst there’s a huge need to develop new protein biomarkers as yet biomarker development and delivery is proving very challenging.  Why is this?

This presentation will demonstrate how SRM/MRM on triple quadrupole mass spectrometers affords huge potential as a platform for the development of specific and sensitive 'biomarker signatures' comprising multiple proteins.   Strategies for the delivery and implementation of multiplexed protein biomarkers to support improved clinical decision making following prostate cancer diagnosis will be described.

Learning Objectives:

1. Appreciate the challenges faced in the management of prostate cancer
2. Recognise the need for authentic protein biomaker discovery and strategies to acheive it
3. Undertand how MRM can be used for the development of analytically validated protein biomarker signatures.
4. Appreciate the challenges associated with the delivery of biomarker signatures for routine use and improved prostate cancer patient outcomes.

 

 

For Research Use Only. Not for use in diagnostic procedures.

 


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
APR 21, 2021 5:00 PM CEST
APR 21, 2021 5:00 PM CEST
Date: April 21, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Spatial Answers Trilogy - Spatial Answers in Immunology Immunology Researchers share their Spatial Discoveries in SARS-C...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
OCT 09, 2019 9:00 AM PDT

Start at the End: A Strategy for Developing and Delivering Advanced Diagnostic Tests to improve Prostate Cancer Patient Outcomes

Sponsored by: Agilent
C.E. Credits: P.A.C.E. CE Florida CE

Specialty

Molecular Biology

Cell Biology

Immunology

Animal Research

Molecular Diagnostics

Human Biology

Hematology

Gene Sequencing

Stem Cell Technologies

Cancer Diagnostics

Dna Sequencing

Neuroscience

Biomarkers

Diagnostics

Assay Development

Geography

North America67%

Asia33%

Registration Source

Website Visitors100%

Job Title

Facility/Department Manager50%

Educator/Faculty50%

Organization

Academic Institution67%

Clinical Laboratory33%


Show Resources
Loading Comments...
Show Resources